Overview

• US gene editing firm's Q1 collaboration revenue fell yr/yr, net loss narrowed

• Company presented positive Phase 3 lonvo-z data and began rolling BLA submission for HAE

• Cash resources, including April offering, expected to fund operations at least into 2028

Outlook

• Company expects to complete BLA submission for lonvo-z in second half of 2026

• Intellia anticipates potential U.S. launch of lonvo-z in first half of 2027

• Company expects existing cash resources to fund operations at least into 2028

Result Drivers

• LOWER R&D SPENDING - Co said reduced research materials, contracted services, employee expenses, and stock-based compensation drove lower R&D costs

• HIGHER G&A COSTS - Co attributed higher G&A expenses to commercial infrastructure buildout and increased legal expenses

Company press release: ID:nGNXbXBzp1

Key Details

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.